Which has the lower trailing P/E, ARQT or TMDX?

TMDX has the lower trailing P/E: ARQT trades at 120.62 and TMDX at 21.73. P/E is one valuation measure and does not by itself establish which business is cheaper.

Is ARQT or TMDX more profitable?

TMDX runs the higher net margin — ARQT at 6.15% versus TMDX at 22.69%.

How have ARQT and TMDX total returns compared?

Over the past 5 years, ARQT delivered -0.28% and TMDX delivered 21.77% annualized total return. Past performance doesn't predict future results.

Arcutis Biotherapeutics, Inc. (ARQT) vs TransMedics Group, Inc. (TMDX)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARQT

Arcutis Biotherapeutics, Inc.

$3.15B

$25.15HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

TMDX

TransMedics Group, Inc.

$2.90B

$83.87HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

Total return — ARQT vs TMDX

growth of $100 · dividends reinvested · last 7y

ARQT +15.4% (+2.1%/yr)TMDX +364.7% (+24.5%/yr)TMDX compounded faster over this window

ARQT TMDX

ARQT vs TMDX: by the numbers

•ARQT is the larger company ($3.15B vs $2.90B market cap).
•TMDX trades at the lower trailing earnings multiple (21.73 vs 120.62 P/E), one valuation lens rather than an overall verdict.
•TMDX converts more revenue to profit (22.69% vs 6.15% net margin).

Metrics side by side

Valuation

Metric	ARQT	TMDX
P/E ratio	120.62	21.73
Forward P/E	50.59	57.17
P/S ratio	6.78	4.34
P/B ratio	14.26	5.60
EV / EBITDA	86.71	27.91
FCF yield	1.24%	2.73%

Profitability

Metric	ARQT	TMDX
Gross margin	91.14%	58.69%
Operating margin	-3.25%	12.21%
Net margin	6.15%	22.69%
ROE	12.93%	29.28%
ROIC	9.95%	5.87%

Growth (annualized)

Metric	ARQT	TMDX
Revenue CAGR (5Y)	N/A	86.12%
Total return CAGR (5Y)	-0.28%	21.77%

Frequently asked

Which has the lower trailing P/E, ARQT or TMDX?: TMDX has the lower trailing P/E: ARQT trades at 120.62 and TMDX at 21.73. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is ARQT or TMDX more profitable?: TMDX runs the higher net margin — ARQT at 6.15% versus TMDX at 22.69%.
How have ARQT and TMDX total returns compared?: Over the past 5 years, ARQT delivered -0.28% and TMDX delivered 21.77% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARQT analysis Full TMDX analysis Interactive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratio TransMedics P/E ratio Arcutis Biotherapeutics ROE TransMedics ROE Arcutis Biotherapeutics operating margin TransMedics operating margin Arcutis Biotherapeutics revenue growth TransMedics revenue growth Arcutis Biotherapeutics free cash flow TransMedics free cash flow

Arcutis Biotherapeutics & TransMedics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.